271 related articles for article (PubMed ID: 29970892)
21. Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.
Sasaki Y; Hamaguchi T; Yamada Y; Takahashi N; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Nagai Y; Taniguchi H; Boku N; Ushijima T; Shimada Y
Asian Pac J Cancer Prev; 2016; 17(2):539-43. PubMed ID: 26925640
[TBL] [Abstract][Full Text] [Related]
22. Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.
Christensen TD; Palshof JA; Larsen FO; Poulsen TS; Høgdall E; Pfeiffer P; Jensen BV; Yilmaz MK; Nielsen D
Acta Oncol; 2018 Aug; 57(8):1057-1062. PubMed ID: 29380640
[TBL] [Abstract][Full Text] [Related]
23. Highly sensitive detection of the PIK3CA (H1047R) mutation in colorectal cancer using a novel PCR-RFLP method.
Li WM; Hu TT; Zhou LL; Feng YM; Wang YY; Fang J
BMC Cancer; 2016 Jul; 16():454. PubMed ID: 27405731
[TBL] [Abstract][Full Text] [Related]
24. KRAS and PIK3CA mutations in colorectal adenocarcinomas correlate with aggressive histological features and behavior.
Jang S; Hong M; Shin MK; Kim BC; Shin HS; Yu E; Hong SM; Kim J; Chun SM; Kim TI; Choi KC; Ko YW; Kim JW
Hum Pathol; 2017 Jul; 65():21-30. PubMed ID: 28188750
[TBL] [Abstract][Full Text] [Related]
25. XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.
Ehrenschwender M; Bittner S; Seibold K; Wajant H
Cell Death Dis; 2014 Dec; 5(12):e1570. PubMed ID: 25501831
[TBL] [Abstract][Full Text] [Related]
26. Detection of PIK3CA Mutations in Plasma DNA of Colorectal Cancer Patients by an Ultra-Sensitive PNA-Mediated PCR.
Zeng Q; Xie L; Zhou N; Liu M; Song X
Mol Diagn Ther; 2017 Aug; 21(4):443-451. PubMed ID: 28247181
[TBL] [Abstract][Full Text] [Related]
27. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R
Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995
[TBL] [Abstract][Full Text] [Related]
28.
Xu JM; Wang Y; Wang YL; Wang Y; Liu T; Ni M; Li MS; Lin L; Ge FJ; Gong C; Gu JY; Jia R; Wang HF; Chen YL; Liu RR; Zhao CH; Tan ZL; Jin Y; Zhu YP; Ogino S; Qian ZR
Clin Cancer Res; 2017 Aug; 23(16):4602-4616. PubMed ID: 28424201
[No Abstract] [Full Text] [Related]
29. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
Arjumand W; Merry CD; Wang C; Saba E; McIntyre JB; Fang S; Kornaga E; Ghatage P; Doll CM; Lees-Miller SP
Oncotarget; 2016 Dec; 7(50):82424-82439. PubMed ID: 27489350
[TBL] [Abstract][Full Text] [Related]
30. GPR48, a poor prognostic factor, promotes tumor metastasis and activates β-catenin/TCF signaling in colorectal cancer.
Wu J; Xie N; Xie K; Zeng J; Cheng L; Lei Y; Liu Y; Song L; Dong D; Chen Y; Zeng R; Nice EC; Huang C; Wei Y
Carcinogenesis; 2013 Dec; 34(12):2861-9. PubMed ID: 23803691
[TBL] [Abstract][Full Text] [Related]
31. Analysis of KRAS, NRAS, BRAF, and PIK3CA mutations could predict metastases in colorectal cancer: A preliminary study.
Wojas-Krawczyk K; Kalinka-Warzocha E; Reszka K; Nicoś M; Szumiło J; Mańdziuk S; Szczepaniak K; Kupnicka D; Lewandowski R; Milanowski J; Krawczyk P
Adv Clin Exp Med; 2019 Jan; 28(1):67-73. PubMed ID: 30085422
[TBL] [Abstract][Full Text] [Related]
32. Colorectal cancer cell-derived exosomes containing miR-10b regulate fibroblast cells via the PI3K/Akt pathway.
Dai G; Yao X; Zhang Y; Gu J; Geng Y; Xue F; Zhang J
Bull Cancer; 2018 Apr; 105(4):336-349. PubMed ID: 29496262
[TBL] [Abstract][Full Text] [Related]
33. Mutation-Associated Phenotypic Heterogeneity in Novel and Canonical PIK3CA Helical and Kinase Domain Mutants.
Ghodsinia AA; Lego JMT; Garcia RL
Cells; 2020 Apr; 9(5):. PubMed ID: 32365913
[TBL] [Abstract][Full Text] [Related]
34. Expression of Lgr5, a marker of intestinal stem cells, in colorectal cancer and its clinicopathological significance.
He S; Zhou H; Zhu X; Hu S; Fei M; Wan D; Gu W; Yang X; Shi D; Zhou J; Zhou J; Zhu Z; Wang L; Li D; Zhang Y
Biomed Pharmacother; 2014 Jun; 68(5):507-13. PubMed ID: 24751002
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population.
Abubaker J; Bavi P; Al-Harbi S; Ibrahim M; Siraj AK; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
Oncogene; 2008 Jun; 27(25):3539-45. PubMed ID: 18193083
[TBL] [Abstract][Full Text] [Related]
36. Clinical Impact and Prognostic Role of KRAS/BRAF/PIK3CA Mutations in Stage I Colorectal Cancer.
Reggiani Bonetti L; Barresi V; Maiorana A; Manfredini S; Caprera C; Bettelli S
Dis Markers; 2018; 2018():2959801. PubMed ID: 30018674
[TBL] [Abstract][Full Text] [Related]
37. Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells.
Zumwalt TJ; Wodarz D; Komarova NL; Toden S; Turner J; Cardenas J; Burn J; Chan AT; Boland CR; Goel A
Cancer Prev Res (Phila); 2017 Mar; 10(3):208-218. PubMed ID: 28154202
[TBL] [Abstract][Full Text] [Related]
38. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
[TBL] [Abstract][Full Text] [Related]
39. Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells.
Kim HJ; Lee SY; Kim CY; Kim YH; Ju W; Kim SC
Oncotarget; 2017 Jan; 8(4):6608-6622. PubMed ID: 28036259
[TBL] [Abstract][Full Text] [Related]
40. HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.
Ghosh A; Lai C; McDonald S; Suraweera N; Sengupta N; Propper D; Dorudi S; Silver A
Exp Mol Pathol; 2013 Feb; 94(1):103-8. PubMed ID: 22982087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]